New tests launched in May


New Tests

In May 2022, Mayo Clinic Laboratories announced eighteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

The new tests that launched in May 2022 by Mayo Clinic Laboratories:

ADMPU | Addiction Medicine Profile with Reflex, 22 Drug Classes, High Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine

This test is useful for detecting drug use involving stimulants, barbiturate, benzodiazepines, cocaine, opioids, tetrahydrocannabinol, alcohol, and nicotine.

CARU | Cyclic Adenosine Monophosphate (cAMP), Urinary Excretion, Serum and Urine

This test is useful in the differential diagnosis of hypercalcemia. Adjunct to serum parathyroid hormone measurements, especially in the diagnosis of parathyroid hormone resistance states, such as pseudohypoparathyroidism.

DEXA | Dexamethasone, Serum

This test is intended for confirming the presence of dexamethasone in serum and confirming the cause of secondary adrenal insufficiency.

FBSQU | Bath Salts Panel (Qualitative), Urine

This test is intended for identifying alpha-PHP and alpha-PiHP, psychoactive stimulants of the pyrrolidinophenone series that are structurally related to alpha-PVP. 

FCIC3 | Circulating Immune Complex, C3 fragments

This test is useful for the detection of circulating immune complexes.

FMITU | Mitragynine (Qualitative), Urine

This test is useful for the identification of Mitragynine, an alkaloid found in the plant Kratom which originates from Asia

HIQDR | HIV-1 RNA Quantification with Reflex to Genotypic Drug Resistance to Reverse Transcriptase, Protease, and Integrase Inhibitors, Plasma

This test is useful for quantifying plasma HIV-1 RNA levels (viral load) in individuals (including children) with known HIV-1 infection, followed by identification of HIV-1 genotypic mutations associated with resistance to nucleotide and non-nucleoside reverse-transcriptase inhibitors protease inhibitors , and integrase strain transfer inhibitors.

This test is also useful for guiding initiation or change of combination antiretroviral therapy in individuals, including children, with HIV-1 infection.

HIVDR | HIV-1 Genotypic Drug Resistance to Reverse Transcriptase, Protease, and Integrase Inhibitors, Plasma

This test is useful for identifying HIV-1 genotypic mutations associated with resistance to nucleotide and non-nucleoside reverse-transcriptase inhibitors, protease inhibitors, and integrase strain transfer inhibitors.

This test is also useful for guiding initiation or change of combination antiretroviral therapy in individuals, including children, with HIV-1 infection.

IGD | Immunoglobulin D (IgD), Serum

This test is useful for providing information on the humoral immune status and identifying an IgD monoclonal gammopathy.

NAT2Q | N-Acetyltransferase 2 (NAT2) Genotype, Varies

This test is intended for identifying patients who may be at risk for altered metabolism of drugs that are substrates of arylamine N-acetyltransferase type 2 (NAT2), including isoniazid.

POWVB | Powassan Virus, RNA, Molecular Detection, PCR, Blood

This test is intended for rapid testing for Powassan virus RNA (lineage 1 and lineage 2) using whole blood specimens, as well as an adjunctive test to serology for detection of early Powassan virus infection (ie, first few days after symptom onset).

POWVC | Powassan Virus, RNA, Molecular Detection, PCR, Spinal Fluid

This test is intended for rapid testing for Powassan virus RNA (lineage 1 and lineage 2) using cerebrospinal fluid specimens and as an adjunctive test to serology for detection of early Powassan virus infection (ie, first few days after symptom onset).

POWVS | Powassan Virus, RNA, Molecular Detection, PCR, Serum

This test is useful for rapid testing for Powassan virus RNA (lineage 1 and lineage 2) using serum specimens, as well as an adjunctive test to serology for detection of early Powassan virus infection (ie, first few days after symptom onset). 

POWVU | Powassan Virus, RNA, Molecular Detection, PCR, Random, Urine

This test is useful for rapid testing for Powassan virus RNA (lineage 1 and lineage 2) using random urine specimens, as well as an adjunctive test to serology for detection of early Powassan virus infection (ie, first few days after symptom onset).

RO52 | Ro52 Antibody, IgG, Serum

This test is useful for the detection of anti- SSA 52 (Ro52) antibodies in serum.

RO60 | Ro60 Antibody, IgG, Serum

This test is useful for the detection of anti-SSA 60 (Ro60) antibodies in serum.

ROPAN | Ro52 and Ro60 Antibodies, IgG, Serum

This test is useful for the detection of anti-SSA 52 (Ro52) or SSA 60 (Ro60) antibodies in serum.

SEMA3 | Semaphorin 3B (SEMA3B) Immunostain, Technical Component Only

This test is useful for aiding in the diagnosis of semaphorin 3B-associated membranous nephropathy.

In addition to these tests, the department also announced several test changes. Click the links below to view test changes announced by Mayo Clinic Laboratories:

Meghann Southwick (@meghannsouthwick)

Meghann Southwick

Meghann Southwick is a marketing specialist for Mayo Clinic Laboratories. She has worked at Mayo Clinic since 2021.